Bayer's MRI Contrast Agent Gets Panel Endorsement, But Without Comparative Safety Claims
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA's Peripheral and Central Nervous System Drugs Advisory Committee declines to deem gadobutrol "lower risk" for causing nephrogenic systemic fibrosis.
You may also be interested in...
Guerbet Looks To Separate Dotarem In Crowded Contrast Agent Market
FDA advisory committee scheduled for Valentine’s Day is key test for Guerbet’s efforts to get its MRI imaging agent a wider indication than Bayer’s Gadavist.
FDA Reestablishes Imaging Drugs Committee, Citing Application Surge
The increasing number of new medical imaging drugs FDA is asked to review has led the agency to reestablish an advisory committee devoted exclusively to them.
FDA Reestablishes Imaging Drugs Committee, Citing Application Surge
The increasing number of new medical imaging drugs FDA is asked to review has led the agency to reestablish an advisory committee devoted exclusively to them.